Surrogate endpoints for overall survival in advanced colorectal cancer: A clinician's perspective

Statistical Methods in Medical Research

Volumn 17, Issue 5, 2008, Pages 519-527

  Piedbois, Pascal ^a   Miller Croswell, Jennifer ^b  

^a ASTRAZENECA   (United Kingdom)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RALTITREXED;

ADVANCED CANCER; BLOOD TOXICITY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FUNCTIONAL ASSESSMENT; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MEDICAL LITERATURE; MEDLINE; MONOTHERAPY; OUTCOMES RESEARCH; OVERALL SURVIVAL; PREDICTION; RELIABILITY; TREATMENT INDICATION; TREATMENT RESPONSE; VALIDATION STUDY;

ATTITUDE OF HEALTH PERSONNEL; BIBLIOMETRICS; BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; HUMANS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS;

EID: 52649094924     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1177/0962280207081865     Document Type: Conference Paper

References (31)

1. Code of Federal Regulations 21; 314. 510. Accessed 16 November 2006, from http://www.fda.gov/cder/rdmt/accapp.htm16
2. Prentice RL Surrogate endpoints in clinical trials: Definition and operational criteria. Statistics in Medicine 1989; 8: 431-40.
3. Buyse M., Molenberghs G., Burzykowski T., Renard D., Geys H. The Validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000; 1: 49-68.
4. Fleming TR Objective response rate as a surrogate end point: A commentary. Journal of Clinical Oncology 2005; 23: 4845-6.
5. Freedman LS, Graubard BL, Schatzkin A. Statistical validation of intermediate end points for chronic diseases. Statistics in Medicine 1992; 11: 167-78.
6. De Gruttola V., Fleming T., Lin DY, Coombs R. Perspective: Validating surrogate markers-are we being naive? Journal of Infectious Diseases. 1997; 175: 237-46.
7. Lin DY, Fleming TR, DeGruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Statistics in Medicine 1997; 16: 1515-27.
8. Parkin DM, Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000. International Journal of Cancer 2001; 94: 153-6.
9. Aggarwal S., Chu E. Current therapies for advanced colorectal cancers. Oncology 2005; 19: 589-95.
10. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts S. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. Journal of Clinical Oncology 2006; 24: 3347-53.
11. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2004; 350: 2335-42. 2335-42.
12. Rougier P., Lepere C. Second-line treatment of patients with metastatic colorectal cancer. Seminars in Oncology 2005; 32: S48-54.
13. Johnson KR, Ringlard C., Stokes BJ et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: A meta-analysis. Lancet Oncology 2006; 7: 741-6.
14. Locker GY, Hamilton S., Harris J., Jessup JM, Kemeny N., Macdonald JS, Somerfield MR, Hayes DF, Bast Jr RC; Asco. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. Journal of Clinical Oncology 2006; 24: 5313-27.
15. Therasse P., Arbuck SG, Eisenhauer EA, Wanders J., Kaplan RS, Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom AT, Christian MC, Gwyther SG New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000; 92: 205-16.
16. Miller AB, Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
17. Buyse M., Thirion P., Carlson RW, Burzykowski T., Molenberghs G., Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advancedcolorectal cancer: A meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000; 356: 373-8.
18. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the evaluation of anticancer medicinal products in man. CPMP/EWP/205/95.
19. Buyse (paper published in the present issue of the Journal) 2007.
20. Fleming TR, DeMets DL Surrogate endpoints in clinical trials: Are we being misled? Annals of Internal Medicine 1996; 125(7): 605-13.
21. Gail MH, Pfeiffer R., Van Houwelingen HC, Carroll RJ On meta-analytic assessment of surrogate outcomes. Biostatistics 2000; 1(3): 231-46.
22. Katz R. Biomarkers and surrogate markers: An FDA perspective. NeuroRx 2004; 1(2): 189-95.
23. Baker SG, Kramer BS A perfect correlate does not a surrogate make. BMC Medical Research Methodology 2003. Accessed 14 November 2006, from http://www.biomedcentral.com/1471-2288/3/16
24. Starling N., Chau I., Norman AR, Tait D., Iveson T., Hill M., Hickish T., Lofts F., Jodrell D., Cunningham D. A randomised comparison between six months of bolus fluorouracil (5-FU)/leucovorin (LV) and twelve weeks of protracted venous infusion (PVI) 5-FU as adjuvant treatment in colorectal cancer: An update with 5 years' follow-up. Proceedings of the American Society of Clinical Oncology 2004; 23: 3523.
25. Holen KD Target practice: Figuring out which, when, and why to use systemic therapies for metastatic colon cancer. Cancer Investigation 2006; 24: 98-105.
26. Meta-Analysis Group In Cancer. Toxicity of 5-fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. Journal of Clinical Oncology 1998; 16: 3537-41.
27. Fleming TR Surrogate endpoints and FDA's accelerated approval process. Health Affairs 2005; 24(1): 67-78.
28. Hughes MD Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer. Statistical Methods in Medical Research 2008; 17: 487-95.
29. Green EM, Yothers G. and Sargent DJ Surrogate endpoint validation: statistical elegance versus clinical relevance. Statistical Methods in Medical Research 2008; 17: 477-86.
30. Baker SG Two simple approaches for validating a binary surrogate endpoint using data from multiple trials. Statistical Methods in Medical Research 2008; 17: 505-14.
31. Alonso A. and Molenberghs G. Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective. Statistical Methods in Medical Research 2008; 17: 497-504.